Current status of anti-angiogenesis therapy for prostate cancer{star, open}

Juan Antonio Jiménez, Chinghai Kao, Sudhanshu Raikwar, Thomas A. Gardner

Research output: Contribution to journalReview article

18 Scopus citations

Abstract

Prostate cancer is the second leading cause of cancer mortality in American men and the single most diagnosed cancer in men. Despite advances in early detection and conventional treatment strategies, prostate cancer progresses and becomes resistant to treatment. Because tumor growth and establishment of metastases are dependent on angiogenesis, interest in the development of anti-angiogenesis therapies has grown. Preclinical studies and early clinical evaluation show promise in the adjunctive use of anti-angiogenesis to overcome the limitations of current therapeutic approaches. In this review, we outline the basic science principles of angiogenesis and their application in the development of anticancer therapies.

Original languageEnglish (US)
Pages (from-to)260-268
Number of pages9
JournalUrologic Oncology: Seminars and Original Investigations
Volume24
Issue number3
DOIs
StatePublished - May 1 2006

    Fingerprint

Keywords

  • Adenovirus
  • Anti-angiogenesis
  • Gene therapy
  • Prostate cancer
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this